Carmed Pharmaceuticals, a Turkey-based science-driven company specializing in standardized carvacrol-based formulations, has earned editorial coverage in CityBiz through a featured executive Q&A with Founder Mustafa Can as the company continues expanding into the United States market. The interview explores Can’s unconventional journey from ship master in the maritime industry to founder of a research-focused pharmaceutical company built around standardized botanical formulations and long-term scientific development.
In the interview, Can explains how a personal interest in longevity and preventive wellness led him into years of independent research studying botanical compounds and formulation science before formally establishing Carmed Pharmaceuticals. “Over time, this personal journey evolved into something more structured,” Can said. “I became increasingly focused on how to develop standardized, reproducible formulations based on bioactive compounds like carvacrol.” The article also highlights Carmed’s emphasis on what the company describes as “rational synergy” – combining multiple bioactive compounds within standardized formulations designed around consistency, reproducibility, and analytical validation.
The CityBiz placement comes as Carmed continues building awareness in the United States through a multi-channel distribution strategy that includes both curated wellness platforms and large-scale digital marketplaces. Several Carmed formulations are now available on OneLavi.com, including Vacrol® Kids Spray, S-Mix®, Vacrol® Capsule, and Vacrol-M® Capsule. Vacrol® Kids Spray and S-Mix® are gluten-free, non-GMO, sugar-free, preservative-free, and halal-certified. The company also previously announced plans to expand availability through Amazon as part of its broader U.S. rollout strategy.
“We believe educational visibility and accessibility must develop together,” said Ceren Can, Global Brand Director of Carmed Pharmaceuticals. “The CityBiz feature helps communicate the philosophy behind Carmed while platforms like OneLavi and Amazon help make our formulations more accessible to consumers in the United States.”
The CityBiz interview also discusses Carmed’s commitment to scientific collaboration and ongoing research. According to the feature, Carmed works alongside physicians, researchers, laboratories, and academic partners to support formulation development and scientific evaluation. In January 2026, research involving Carmed formulations Vacrol® and S-Mix® was published in the peer-reviewed journal Plants, where the formulations were examined in preclinical laboratory and in ovo models as part of broader scientific investigation into carvacrol-based botanical formulations. The company emphasizes that this research reflects scientific investigation into formulation science and botanical bioactivity and is not presented as evidence that its consumer products diagnose, treat, cure, or prevent any disease.
Carmed states that its U.S. strategy is focused on long-term brand development through scientific credibility, regulatory alignment, educational visibility, and expanded consumer accessibility. “Our goal is to build a company that is known for consistency, credibility, and a long-term commitment to research-driven development,” Can said. The full CityBiz Q&A with Mustafa Can can be viewed here.
This expansion into the U.S. market represents a significant step for Carmed as it seeks to establish a presence in the competitive wellness industry. The company’s focus on standardized, research-backed formulations could resonate with consumers increasingly seeking science-based preventive health products. By leveraging both educational media coverage and e-commerce platforms, Carmed aims to build credibility and accessibility simultaneously, potentially setting a precedent for other international botanical formulation companies entering the U.S. market.
